• Biocon Ltd. is India’s premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
• Established in 1978 by Ms Kiran Mazumdar-Shaw, Biocon is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases.
• Biocon’s key innovations include world’s first Pichia-based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG®, and India’s first indigenously produced monoclonal antibody, BioMAb EGFR® , for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon.
• Continuing on its commitment of affordable innovation, Biocon has delivered its second novel biologic, Itolizumab, a ‘first in class’ biologic drug and the world’s only anti-CD6 monoclonal antibody. Itolizumab will be commercialized in India as ALZUMAb™.
• Biocon’s consolidated revenue for FY 13 stands at Rs 25380 million (USD 467 million). Biocon is focused on attaining a size of USD 1 billion by 2018.